Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The objective of this study was to analyze the impact of age on clinical outcomes of metastatic renal cell carcinoma (mRCC) patients receiving axitinib. This study included 144 consecutive mRCC patients who received axitinib for at least 12 weeks as second-line therapy in a routine clinical setting. The efficacy, safety and quality of life (QOL) were compared between patients aged <75 (n = 116) and ≥75 (n = 28) years. No significant differences in the clinicopathological characteristics were noted between younger and older patients. There was no significant difference in the response rate, clinical benefit rate or proportion of patients going on to receive third-line therapy between these two groups. In addition, the progression-free and overall survivals in older patients were similar to those in younger patients. There were no significant differences in the incidences of adverse events between these two groups, except for that of fatigue, which was significantly more frequent in older than younger patients. There was no significant difference in the incidence of the discontinuation of axitinib due to adverse events between the two groups. QOL assessment at 12 weeks after the introduction of axitinib using the Medical Outcomes Study 36-Item Short Form showed no significant differences in any of the eight scale scores between the two groups. Taken together, it might be possible to achieve clinical outcomes in older patients receiving axitinib comparable to those in younger patients, suggesting that advanced age should not be a contraindication to treatment with axitinib as a second-line setting in mRCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Janssen-Heijnen ML, Gondos A, Bray F, et al. Clinical relevance of conditional survival of cancer patients in Europe: age-specific analyses of 13 cancers. J Clin Oncol. 2010;28:2520–8.

    Article  PubMed  Google Scholar 

  2. Pal SK, Vanderwalde A, Hurria A, et al. Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging. 2011;28:635–49.

    Article  CAS  PubMed  Google Scholar 

  3. Verhoest G, Veillard D, Guillé F, et al. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol. 2007;51:1298–304.

    Article  PubMed  Google Scholar 

  4. Thompson RH, Ordonez MA, Iasonos A, et al. Renal cell carcinoma in young and old patients—is there a difference? J Urol. 2008;180:1262–6.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Extermann M. Basic assessment of the older cancer patient. Curr Treat Options Oncol. 2011;12:276–85.

    Article  PubMed  Google Scholar 

  6. Figlin R, Sternberg C, Wood CG. Novel agents and approaches for advanced renal cell carcinoma. J Urol. 2012;188:707–15.

    Article  CAS  PubMed  Google Scholar 

  7. Kelly RJ, Rixe O. Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol. 2009;4:297–305.

    Article  PubMed  Google Scholar 

  8. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14:7272–83.

    Article  CAS  PubMed  Google Scholar 

  9. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.

    Article  CAS  PubMed  Google Scholar 

  10. Oudard S, Elaidi RT. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat Rev. 2012;38:981–7.

    Article  CAS  PubMed  Google Scholar 

  11. Hutson TE, Bukowski RM, Rini BI, et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 2014;110:1125–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Khambati HK, Choueiri TK, Kollmannsberger CK, et al. Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. Clin Genitourin Cancer. 2014;12:354–8.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Brunello A, Basso U, Sacco C, et al. Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study. Ann Oncol. 2013;24:336–42.

    Article  CAS  PubMed  Google Scholar 

  14. Miled OD, Dionne C, Terret C, et al. Sorafenib and sunitinib for elderly patients with renal cell carcinoma. J Geriatr Oncol. 2013;4:255–61.

    Article  Google Scholar 

  15. Pal SK, Hsu J, Hsu S, et al. Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma. J Geriatr Oncol. 2013;4:128–33.

    Article  PubMed  Google Scholar 

  16. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289–96.

    Article  CAS  PubMed  Google Scholar 

  17. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–9.

    Article  CAS  PubMed  Google Scholar 

  18. Fukuhara S, Bito S, Green J. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol. 1998;51:1037–44.

    Article  CAS  PubMed  Google Scholar 

  19. Fukuhara S, Ware JE Jr, Kosinski M. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol. 1998;51:1045–53.

    Article  CAS  PubMed  Google Scholar 

  20. Dutcher JP, Tannir N, Bellmunt J, et al. Experience with sorafenib and the elderly patient. Med Oncol. 2010;27:1359–70.

    Article  PubMed  Google Scholar 

  21. Meehan B, Appu S, St Croix B, et al. Age-related properties of the tumour vasculature in renal cell carcinoma. BJU Int. 2011;107:416–24.

    Article  PubMed  Google Scholar 

  22. Kondo K, Klco J, Nakamura E, et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel–Lindau protein. Cancer Cell. 2002;1:237–46.

    Article  CAS  PubMed  Google Scholar 

  23. Nelson RA, Vogelzang N, Pal SK. A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis. Clin Genitourin Cancer. 2013;11:303–10.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Eiser C, Penn A, Katz E, et al. Psychosocial issues and quality of life. Semin Oncol. 2009;36:275–80.

    Article  PubMed  Google Scholar 

  25. Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int. 2009;103:572–7.

    Article  CAS  PubMed  Google Scholar 

  26. Wada Y, Takahashi W, Kawano Y, et al. Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan. Int J Urol. 2012;19:284–95.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan

    Hideaki Miyake, Ken-ichi Harada & Masato Fujisawa

  2. Department of Urology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu, 431-3192, Japan

    Hideaki Miyake & Seiichiro Ozono

Authors
  1. Hideaki Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken-ichi Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seiichiro Ozono
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masato Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideaki Miyake.

Ethics declarations

Conflict of interest

H. Miyake, KI. Harada, S. Ozono and M. Fujisawa have received lecture fees from Pfizer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miyake, H., Harada, Ki., Ozono, S. et al. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma. Med Oncol 33, 95 (2016). https://doi.org/10.1007/s12032-016-0813-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-016-0813-1

Keywords

Search

Navigation